FDA Approvals

FDA Approves Pembrolizumab for Solid Tumors with MSI-H or dMMR Mutations for Select Patients

On March 29, 2023, the U.S. Food and Drug Administration approved pembrolizumab for adult and pediatric patients with unresectable or…

2 years ago

FDA Approves Retifanlimab-dlwr for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma

On March 22, 2023, the U.S. Food and Drug Administration granted accelerated approval to retifanlimab-dlwr — a humanized monoclonal antibody…

2 years ago